KRAS Mutation Analysis
Expected Turnaround Time
14 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
This assay detects mutations in KRAS. KRAS mutations serve as an independent predictor of colorectal cancer (CRC) and patient responsiveness to EGFR (TKI) inhibitor therapy.
Requisition Forms
Specimen Requirements
Specimen Requirements
- Paraffin Embedded Tissue Block: FFPE Block, 10% NBF Fixed
- Paraffin Embedded Tissue Slides: 5 slides or scrolls (minimum 5-10 μM), 10% NBF Fixed
Specimen Stability
Indefinite
Storage Requirements
15°C to 25°C
Shipping Conditions
Ambient
Shipping Recommendations
AMBIENT, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen.
Specimen Rejection Criteria
Improper specimen labeling; Insufficient tissue; Insufficient tumor burden; Insufficient DNA isolated
Test Details
Synonyms
KRAS2
Keywords
Companion Diagnostics, Molecular Diagnostics, Oncology, Mutation Analysis, DNA Sequencing, Gastrointestinal Cancer, Lung Cancer, Genomics, Next Generation Sequencing
Test Method
Next Generation Sequencing (NGS)
Methodology Category
Molecular
Regulatory Status
RUO
Special Considerations
- FFPE block preferred; unbaked slides acceptable.
- Include a surgical pathology report with the sample
Associations
EGFR inhibitor, Colorectal cancer, NSCLC; Tyrosine kinase inhibitors (TKI)
Get Expert Guidance on KRAS Mutation Analysis
Our laboratory specialists can help you understand test requirements, methodology, and interpretation.
Connect with an Expert Today